Kite, a Gilead Company, today announced the U.S. Food and Drug Administration has granted approval for Tecartus ® for the treatment of adult patients with relapsed or refractory B-cell precursor acute ...
Santa Monica-based Kite Pharma announced March 5 that the Food and Drug Administration has granted accelerated approval for the company’s principal drug, Yescarta, for the treatment of adult patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback